Gelatin-based biodegradable ureteral stents for the treatment of urothelial tumors of the upper urinary tract cancer

Bibliographic Details
Main Author: Barros, Alexandre António Antunes
Publication Date: 2016
Other Authors: Browne, S., Oliveira, C., Lima, Estêvão Augusto Rodrigues de, Duarte, Ana Rita C., Healy, K. E., Reis, R. L.
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/1822/47096
Summary: Upper urinary tract urothelial carcinoma (UTUC) accounts for 5â 10% of urothelial carcinomas and is a disease that has not been widely studied as carcinoma of the bladder. To avoid the problems of conventional therapies, such as the need for frequent drug instillation due to poor drug retention, we developed a biodegradable ureteral stent (BUS) impregnated by supercritical fluid CO2 (scCO2) with the most commonly used anti-cancer drugs, namely paclitaxel, epirubicin, doxorubicin, and gemcitabine. The release kinetics of anti-cancer therapeutics from drug-eluting stents was measured in artificial urine solution (AUS). The in vitro release showed a faster release in the first 72h for the four anti-cancer drugs, after this time a plateau was achieved and finally the stent degraded after 9 days. Regarding the amount of impregnated drugs by scCO2, gemcitabine showed the highest amount of loading (19.57â μg drug /mg polymer: 2% loaded), while the lowest amount was obtained for paclitaxel (0.067â μg drug /mg polymer: 0.01% loaded). A cancer cell line (T24) was exposed to graded concentrations (0.01 to 2000â ng/ml) of each drug for 4 and 72 hours to determine the sensitivities of the cells to each drug (IC50). The direct and indirect contact study of the anti-cancer biodegradable ureteral stents with the T24 and HUVEC cell lines confirmed the anti-tumoral effect of the BUS impregnated with the four anti-cancer drugs tested, reducing by 75% of the viability of the T24 cell line after 72h and demonstrating minimal cytotoxic effect on HUVECs.
id RCAP_7e6602cf63c43c5885a88a1d0ba535b6
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/47096
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Gelatin-based biodegradable ureteral stents for the treatment of urothelial tumors of the upper urinary tract cancerCancer cellsDrug-elutingStentsUpper urinary tractScience & TechnologyUpper urinary tract urothelial carcinoma (UTUC) accounts for 5â 10% of urothelial carcinomas and is a disease that has not been widely studied as carcinoma of the bladder. To avoid the problems of conventional therapies, such as the need for frequent drug instillation due to poor drug retention, we developed a biodegradable ureteral stent (BUS) impregnated by supercritical fluid CO2 (scCO2) with the most commonly used anti-cancer drugs, namely paclitaxel, epirubicin, doxorubicin, and gemcitabine. The release kinetics of anti-cancer therapeutics from drug-eluting stents was measured in artificial urine solution (AUS). The in vitro release showed a faster release in the first 72h for the four anti-cancer drugs, after this time a plateau was achieved and finally the stent degraded after 9 days. Regarding the amount of impregnated drugs by scCO2, gemcitabine showed the highest amount of loading (19.57â μg drug /mg polymer: 2% loaded), while the lowest amount was obtained for paclitaxel (0.067â μg drug /mg polymer: 0.01% loaded). A cancer cell line (T24) was exposed to graded concentrations (0.01 to 2000â ng/ml) of each drug for 4 and 72 hours to determine the sensitivities of the cells to each drug (IC50). The direct and indirect contact study of the anti-cancer biodegradable ureteral stents with the T24 and HUVEC cell lines confirmed the anti-tumoral effect of the BUS impregnated with the four anti-cancer drugs tested, reducing by 75% of the viability of the T24 cell line after 72h and demonstrating minimal cytotoxic effect on HUVECs.info:eu-repo/semantics/publishedVersionMary Ann Liebert Inc.Universidade do MinhoBarros, Alexandre António AntunesBrowne, S.Oliveira, C.Lima, Estêvão Augusto Rodrigues deDuarte, Ana Rita C.Healy, K. E.Reis, R. L.2016-122016-12-01T00:00:00Zconference objectinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/1822/47096engBarros A. A., Browne S., Oliveira C., Lima E., Duarte A. R. C., Healy K. E., Reis R. L. Gelatin-based Biodegradable Ureteral Stents For The Treatment Of Urothelial Tumors Of The Upper Urinary Tract Cancer, Tissue Engineering Part A, Vol. 22, Issue S1, doi:10.1089/ten.tea.2016.5000.abstracts., 20162152-4947http://online.liebertpub.com/doi/full/10.1089/ten.tea.2016.5000.abstractsinfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-11T05:35:58Zoai:repositorium.sdum.uminho.pt:1822/47096Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T15:23:44.312840Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Gelatin-based biodegradable ureteral stents for the treatment of urothelial tumors of the upper urinary tract cancer
title Gelatin-based biodegradable ureteral stents for the treatment of urothelial tumors of the upper urinary tract cancer
spellingShingle Gelatin-based biodegradable ureteral stents for the treatment of urothelial tumors of the upper urinary tract cancer
Barros, Alexandre António Antunes
Cancer cells
Drug-eluting
Stents
Upper urinary tract
Science & Technology
title_short Gelatin-based biodegradable ureteral stents for the treatment of urothelial tumors of the upper urinary tract cancer
title_full Gelatin-based biodegradable ureteral stents for the treatment of urothelial tumors of the upper urinary tract cancer
title_fullStr Gelatin-based biodegradable ureteral stents for the treatment of urothelial tumors of the upper urinary tract cancer
title_full_unstemmed Gelatin-based biodegradable ureteral stents for the treatment of urothelial tumors of the upper urinary tract cancer
title_sort Gelatin-based biodegradable ureteral stents for the treatment of urothelial tumors of the upper urinary tract cancer
author Barros, Alexandre António Antunes
author_facet Barros, Alexandre António Antunes
Browne, S.
Oliveira, C.
Lima, Estêvão Augusto Rodrigues de
Duarte, Ana Rita C.
Healy, K. E.
Reis, R. L.
author_role author
author2 Browne, S.
Oliveira, C.
Lima, Estêvão Augusto Rodrigues de
Duarte, Ana Rita C.
Healy, K. E.
Reis, R. L.
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Barros, Alexandre António Antunes
Browne, S.
Oliveira, C.
Lima, Estêvão Augusto Rodrigues de
Duarte, Ana Rita C.
Healy, K. E.
Reis, R. L.
dc.subject.por.fl_str_mv Cancer cells
Drug-eluting
Stents
Upper urinary tract
Science & Technology
topic Cancer cells
Drug-eluting
Stents
Upper urinary tract
Science & Technology
description Upper urinary tract urothelial carcinoma (UTUC) accounts for 5â 10% of urothelial carcinomas and is a disease that has not been widely studied as carcinoma of the bladder. To avoid the problems of conventional therapies, such as the need for frequent drug instillation due to poor drug retention, we developed a biodegradable ureteral stent (BUS) impregnated by supercritical fluid CO2 (scCO2) with the most commonly used anti-cancer drugs, namely paclitaxel, epirubicin, doxorubicin, and gemcitabine. The release kinetics of anti-cancer therapeutics from drug-eluting stents was measured in artificial urine solution (AUS). The in vitro release showed a faster release in the first 72h for the four anti-cancer drugs, after this time a plateau was achieved and finally the stent degraded after 9 days. Regarding the amount of impregnated drugs by scCO2, gemcitabine showed the highest amount of loading (19.57â μg drug /mg polymer: 2% loaded), while the lowest amount was obtained for paclitaxel (0.067â μg drug /mg polymer: 0.01% loaded). A cancer cell line (T24) was exposed to graded concentrations (0.01 to 2000â ng/ml) of each drug for 4 and 72 hours to determine the sensitivities of the cells to each drug (IC50). The direct and indirect contact study of the anti-cancer biodegradable ureteral stents with the T24 and HUVEC cell lines confirmed the anti-tumoral effect of the BUS impregnated with the four anti-cancer drugs tested, reducing by 75% of the viability of the T24 cell line after 72h and demonstrating minimal cytotoxic effect on HUVECs.
publishDate 2016
dc.date.none.fl_str_mv 2016-12
2016-12-01T00:00:00Z
dc.type.driver.fl_str_mv conference object
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1822/47096
url http://hdl.handle.net/1822/47096
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Barros A. A., Browne S., Oliveira C., Lima E., Duarte A. R. C., Healy K. E., Reis R. L. Gelatin-based Biodegradable Ureteral Stents For The Treatment Of Urothelial Tumors Of The Upper Urinary Tract Cancer, Tissue Engineering Part A, Vol. 22, Issue S1, doi:10.1089/ten.tea.2016.5000.abstracts., 2016
2152-4947
http://online.liebertpub.com/doi/full/10.1089/ten.tea.2016.5000.abstracts
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Mary Ann Liebert Inc.
publisher.none.fl_str_mv Mary Ann Liebert Inc.
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833595287639162880